275 related articles for article (PubMed ID: 37403264)
1. Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies.
Loh HP; Mahfut FB; Chen SW; Huang Y; Huo J; Zhang W; Lam KP; Xu S; Yang Y
MAbs; 2023; 15(1):2231129. PubMed ID: 37403264
[TBL] [Abstract][Full Text] [Related]
2. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
[TBL] [Abstract][Full Text] [Related]
3. A novel efficient bispecific antibody format, combining a conventional antigen-binding fragment with a single domain antibody, avoids potential heavy-light chain mis-pairing.
Huang S; Segués A; Hulsik DL; Zaiss DM; Sijts AJAM; van Duijnhoven SMJ; van Elsas A
J Immunol Methods; 2020 Aug; 483():112811. PubMed ID: 32569598
[TBL] [Abstract][Full Text] [Related]
4. RUBY® - a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties.
Nyesiga B; Levin M; Säll A; Rosén A; Jansson K; Fritzell S; Hägerbrand K; Weilguny D; von Schantz L
MAbs; 2024; 16(1):2330113. PubMed ID: 38527972
[TBL] [Abstract][Full Text] [Related]
5. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
6. Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma.
Long AW; Xu H; Santich BH; Guo H; Hoseini SS; de Stanchina E; Cheung NV
J Hematol Oncol; 2024 Apr; 17(1):20. PubMed ID: 38650005
[TBL] [Abstract][Full Text] [Related]
7. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
8. Influence of the bispecific antibody IgG subclass on T cell redirection.
Kapelski S; Cleiren E; Attar RM; Philippar U; Häsler J; Chiu ML
MAbs; 2019; 11(6):1012-1024. PubMed ID: 31242061
[TBL] [Abstract][Full Text] [Related]
9. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
[TBL] [Abstract][Full Text] [Related]
10. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
[TBL] [Abstract][Full Text] [Related]
11. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
13. The eIg technology to generate Ig-like bispecific antibodies.
Kühl L; Aschmoneit N; Kontermann RE; Seifert O
MAbs; 2022; 14(1):2063043. PubMed ID: 35427197
[TBL] [Abstract][Full Text] [Related]
14. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
[TBL] [Abstract][Full Text] [Related]
15. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy.
Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH
MAbs; 2014; 6(2):381-91. PubMed ID: 24492297
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms.
Link BK; Kostelny SA; Cole MS; Fusselman WP; Tso JY; Weiner GJ
Int J Cancer; 1998 Jul; 77(2):251-6. PubMed ID: 9650561
[TBL] [Abstract][Full Text] [Related]
17. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
[TBL] [Abstract][Full Text] [Related]
18. Full-length recombinant antibodies from
Rashid MH
MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
[TBL] [Abstract][Full Text] [Related]
19. Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.
Yu L; Huang N; Ge L; Sun H; Fu Y; Liu C; Wang J
J Biol Eng; 2021 Jun; 15(1):18. PubMed ID: 34187511
[TBL] [Abstract][Full Text] [Related]
20. A novel brick for bispecific antibody construction.
He Y; Ma H; Wang C; Ai Z; Wu Q; Chen H; Lu D
Proteins; 2023 Aug; 91(8):1065-1076. PubMed ID: 36964928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
